Literature DB >> 15361772

Metabolic syndrome and target organ damage in untreated essential hypertensives.

Cesare Cuspidi1, Stefano Meani, Veronica Fusi, Barbara Severgnini, Cristiana Valerio, Eleonora Catini, Gastone Leonetti, Fabio Magrini, Alberto Zanchetti.   

Abstract

BACKGROUND: The prevalence and the relationship between metabolic syndrome, and target organ damage (TOD) in essential hypertensive patients has not been fully explored to date.
OBJECTIVE: To investigate the association between metabolic syndrome, as defined by the ATP III report, and cardiac and extracardiac TOD, as defined by the 2003 ESH-ESC guidelines for management of hypertension, in a large population of never-treated essential hypertensives.
METHODS: A total of 447 grade 1 and 2 hypertensive patients (mean age 46 +/- 12 years) who were attending a hypertension hospital outpatient clinic for the first time underwent the following procedures: (i) physical examination and repeated clinic blood pressure measurements; (ii) routine examinations; (iii) 24-h urine collection for microalbuminuria; (iv) 24-h ambulatory blood pressure monitoring; (v) echocardiography; and (vi) carotid ultrasonography. Metabolic syndrome was defined as involving at least three of the following alterations: increased waist circumference, increased triglycerides, decreased high-density lipoprotein cholesterol, increased blood pressure, or high fasting glucose. Left ventricular hypertrophy (LVH) was defined according to two different criteria: (i) 125 g/m in men and 110 g/m in women; (ii) 51 g/h in men and 47 g/h in women.
RESULTS: The 135 patients with metabolic syndrome (group I) were similar for age, sex distribution, known duration of hypertension and average 24-h, daytime and night-time ambulatory blood pressure to the 312 patients without it (group II). The prevalence of altered left ventricular patterns (LVH and left ventricular concentric remodelling) was significantly higher in group I (criterion a = 30%, criterion b = 42%) than in group II (criterion a = 23%, criterion b = 30%, P < 0.05 and P < 0.01, respectively). A greater urinary albumin excretion (17 +/- 35 versus 11 +/- 23 mg/24 h, P = 0.04) was also found in group I compared to group II. There were no significant differences between the two groups in the prevalence of carotid intima-media thickening and plaques.
CONCLUSIONS: These results from a representative sample of untreated middle-aged hypertensives show that: (i) the metabolic syndrome is highly prevalent in this setting and (ii) despite similar ambulatory blood pressure values, patients with metabolic syndrome have a more pronounced cardiac and extracardiac involvement than those without it.

Entities:  

Mesh:

Year:  2004        PMID: 15361772     DOI: 10.1097/00004872-200410000-00023

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  39 in total

1.  Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: role of the metabolic syndrome.

Authors:  Federico Guerra; Lucia Mancinelli; Alessia Buglioni; Valentina Pierini; Alessandro Rappelli; Paolo Dessì-Fulgheri; Riccardo Sarzani
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-12-01

2.  Insulin resistance explains the relationship between novel cardiovascular risk factors and hypertension. The Telde Study.

Authors:  A M Wägner; J C Wiebe; M Boronat; P Saavedra; D Marrero; F Varillas; F J Nóvoa
Journal:  J Endocrinol Invest       Date:  2010-10-27       Impact factor: 4.256

Review 3.  Management of hypertension in patients with left ventricular hypertrophy.

Authors:  Cesare Cuspidi; Carla Sala; Alberto Zanchetti
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

4.  Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study.

Authors:  G de Simone; R B Devereux; M Chinali; M J Roman; E T Lee; H E Resnick; B V Howard
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-07-31       Impact factor: 4.222

5.  Abnormal cardiac structure and function in the metabolic syndrome: a population-based study.

Authors:  Bilal Aijaz; Khawaja A Ammar; Francisco Lopez-Jimenez; Margaret M Redfield; Steven J Jacobsen; Richard J Rodeheffer
Journal:  Mayo Clin Proc       Date:  2008-12       Impact factor: 7.616

6.  Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis.

Authors:  Ning-Yin Li; Jing Yu; Xiao-Wei Zhang; Shi-Xiong Wang; Peng Chang; Qi Ding; Rui-Xin Ma; Qun-Fei Chen; Feng Zhao; Feng Bai
Journal:  Endocrine       Date:  2013-01-31       Impact factor: 3.633

Review 7.  Insulin and its role in chronic kidney disease.

Authors:  Robert H Mak
Journal:  Pediatr Nephrol       Date:  2007-10-11       Impact factor: 3.714

Review 8.  How to define prehypertension in diabetes/metabolic syndrome.

Authors:  Avshalom Leibowitz; Ehud Grossman
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

9.  Increased inflammation, reduced plasma phospholipid eicosapentaenoic acid and reduced antioxidant potential of treated hypertensive patients with metabolic syndrome.

Authors:  Min-Jeong Shin; Eugene Shim; Borum Kang; Sungha Park; Sang-Hak Lee; Chi Young Shim; Eunju Park; Namsik Chung
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

10.  Associations between plasma homocysteine levels, aortic stiffness and wave reflection in patients with arterial hypertension, isolated office hypertension and normotensive controls.

Authors:  G Vyssoulis; E Karpanou; S-M Kyvelou; D Adamopoulos; T Gialernios; E Gymnopoulou; D Cokkinos; C Stefanadis
Journal:  J Hum Hypertens       Date:  2009-06-11       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.